open access

Vol 8, No 3 (2012)
Review paper
Published online: 2012-08-29
Get Citation

Prophylaxis of venous thromboembolism in patients with cancer

Krzysztof Chojnowski, Jacek Treliński
Onkol. Prak. Klin 2012;8(3):105-112.

open access

Vol 8, No 3 (2012)
REVIEW ARTICLES
Published online: 2012-08-29

Abstract

Patients with cancer are at increased risk of venous thromboembolism (VTE), which is the second frequent
cause of death in this population. This is why implementation of efficient VTE prophylaxis is one of the
most important issues in modern oncology. A variety of guidelines were developed by different Polish
and International oncologic societies. Despite some small differences, all recommendations agree that
VTE prophylaxis should at first concern patients with the highest risk for thrombosis. Acute medical and
surgical conditions are most frequent clinical situations that require prophylaxis with low-molecular weight
heparin, unfractioned heparin or fondaparinux in hospitalized cancer patients. The international guidelines
currently agree in non-recommending routine prophylaxis in ambulatory patients who receive anticancer
chemotherapy with the exception of multiple myeloma patients treated with combined therapy including
antiangiogenic agents (thalidomide and lenalidomide). The routine prophylaxis should not be also applied
in patients with central vein catheter.

Abstract

Patients with cancer are at increased risk of venous thromboembolism (VTE), which is the second frequent
cause of death in this population. This is why implementation of efficient VTE prophylaxis is one of the
most important issues in modern oncology. A variety of guidelines were developed by different Polish
and International oncologic societies. Despite some small differences, all recommendations agree that
VTE prophylaxis should at first concern patients with the highest risk for thrombosis. Acute medical and
surgical conditions are most frequent clinical situations that require prophylaxis with low-molecular weight
heparin, unfractioned heparin or fondaparinux in hospitalized cancer patients. The international guidelines
currently agree in non-recommending routine prophylaxis in ambulatory patients who receive anticancer
chemotherapy with the exception of multiple myeloma patients treated with combined therapy including
antiangiogenic agents (thalidomide and lenalidomide). The routine prophylaxis should not be also applied
in patients with central vein catheter.
Get Citation

Keywords

venous thromboembolism, antithrombotic prophylaxis, low-molecular-weight heparins, fondaparinux

About this article
Title

Prophylaxis of venous thromboembolism in patients with cancer

Journal

Oncology in Clinical Practice

Issue

Vol 8, No 3 (2012)

Article type

Review paper

Pages

105-112

Published online

2012-08-29

Bibliographic record

Onkol. Prak. Klin 2012;8(3):105-112.

Keywords

venous thromboembolism
antithrombotic prophylaxis
low-molecular-weight heparins
fondaparinux

Authors

Krzysztof Chojnowski
Jacek Treliński

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl